mrna1273 Search Results


moderna mrna 1273  (Moderna)
86
Moderna moderna mrna 1273
Moderna Mrna 1273, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/1273+mrna+%D0%B8%D0%BB%D0%B8/pm40908164-146-63-63
Average 86 stars, based on 1 article reviews
moderna mrna 1273 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
mrna-1273 for injection  (ModernaTX Inc)
90
ModernaTX Inc mrna-1273 for injection
Mrna 1273 For Injection, supplied by ModernaTX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc08385554__NEJMoa2109522_protocol-144-22-18
Average 90 stars, based on 1 article reviews
mrna-1273 for injection - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (TriNetX Inc)
90
TriNetX Inc mrna-1273
Mrna 1273, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc09502798-69-13-2
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (BioNTech)
90
BioNTech mrna-1273
Neutralization antibody responses against WA1/2020, B.1.351, and B.1.1.529 SARS-CoV-2 variants post-mRNA vaccination (A–D) Data from the following cohorts are shown: (A) naive individuals 2–4 weeks after the second dose (n = 24), (B) naive individuals 6 months after the second dose (n = 25), (C) recovered individuals who received the primary mRNA vaccination series (n = 37), and (D) naive vaccinated individuals who received a third dose (n = 52). In (A)–(D), the FRNT 50 GMTs for WA1/2020, B.1.351, and B.1.1.529 are shown with respective fold changes in comparison with the WA1/2020. A pie chart above each graph shows the frequency of individuals who have titers above (Responders) or below (Non-responders) the limit of detection (LOD). The connecting lines between the variants represent matched serum samples. The horizontal dashed lines along the x axis indicate the LOD (FRNT 50 GMT = 10). Blue circles represent individuals who received the Moderna <t>mRNA-1273</t> vaccine as the primary vaccine series, and the red circles represent individuals who received the Pfizer-BioNTech BNT162b2 vaccine as the primary vaccine series. Normality of the data was determined using Shapiro-Wilk normality test. Non-parametric pairwise analysis for neutralization titers was performed by Wilcoxon matched pairs signed rank test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
Mrna 1273, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc08784612-86-15-18
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna1273.211  (ClinTrials BioResearch)
90
ClinTrials BioResearch mrna1273.211
Neutralization antibody responses against WA1/2020, B.1.351, and B.1.1.529 SARS-CoV-2 variants post-mRNA vaccination (A–D) Data from the following cohorts are shown: (A) naive individuals 2–4 weeks after the second dose (n = 24), (B) naive individuals 6 months after the second dose (n = 25), (C) recovered individuals who received the primary mRNA vaccination series (n = 37), and (D) naive vaccinated individuals who received a third dose (n = 52). In (A)–(D), the FRNT 50 GMTs for WA1/2020, B.1.351, and B.1.1.529 are shown with respective fold changes in comparison with the WA1/2020. A pie chart above each graph shows the frequency of individuals who have titers above (Responders) or below (Non-responders) the limit of detection (LOD). The connecting lines between the variants represent matched serum samples. The horizontal dashed lines along the x axis indicate the LOD (FRNT 50 GMT = 10). Blue circles represent individuals who received the Moderna <t>mRNA-1273</t> vaccine as the primary vaccine series, and the red circles represent individuals who received the Pfizer-BioNTech BNT162b2 vaccine as the primary vaccine series. Normality of the data was determined using Shapiro-Wilk normality test. Non-parametric pairwise analysis for neutralization titers was performed by Wilcoxon matched pairs signed rank test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
Mrna1273.211, supplied by ClinTrials BioResearch, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273+213/pmc09511634__NEJMoa2208343_appendix-23-26-34
Average 90 stars, based on 1 article reviews
mrna1273.211 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna1273  (AstraZeneca ltd)
90
AstraZeneca ltd mrna1273
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna1273, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna1273/pmc10312218-57-10-6
Average 90 stars, based on 1 article reviews
mrna1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (HealthVerity Inc)
90
HealthVerity Inc mrna-1273
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna 1273, supplied by HealthVerity Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc09507810-126-31-8
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273-vakzine  (Vakzine Projekt Management GmbH)
90
Vakzine Projekt Management GmbH mrna-1273-vakzine
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna 1273 Vakzine, supplied by Vakzine Projekt Management GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/vakzine+mrna+1273+529/pmc07852047-3-0-7
Average 90 stars, based on 1 article reviews
mrna-1273-vakzine - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (CureVac Inc)
90
CureVac Inc mrna-1273
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna 1273, supplied by CureVac Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc08940982-541-33-44
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (NanoCarrier Co)
90
NanoCarrier Co mrna-1273
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna 1273, supplied by NanoCarrier Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc08402990-356-15-25
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (Siemens AG)
90
Siemens AG mrna-1273
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna 1273, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/pmc08842412-3-26-23
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mrna-1273  (BIOQUAL Inc)
90
BIOQUAL Inc mrna-1273
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
Mrna 1273, supplied by BIOQUAL Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mrna1273/mrna+1273/bio_rxiv__2024__12__11__628030-180-29-4
Average 90 stars, based on 1 article reviews
mrna-1273 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Neutralization antibody responses against WA1/2020, B.1.351, and B.1.1.529 SARS-CoV-2 variants post-mRNA vaccination (A–D) Data from the following cohorts are shown: (A) naive individuals 2–4 weeks after the second dose (n = 24), (B) naive individuals 6 months after the second dose (n = 25), (C) recovered individuals who received the primary mRNA vaccination series (n = 37), and (D) naive vaccinated individuals who received a third dose (n = 52). In (A)–(D), the FRNT 50 GMTs for WA1/2020, B.1.351, and B.1.1.529 are shown with respective fold changes in comparison with the WA1/2020. A pie chart above each graph shows the frequency of individuals who have titers above (Responders) or below (Non-responders) the limit of detection (LOD). The connecting lines between the variants represent matched serum samples. The horizontal dashed lines along the x axis indicate the LOD (FRNT 50 GMT = 10). Blue circles represent individuals who received the Moderna mRNA-1273 vaccine as the primary vaccine series, and the red circles represent individuals who received the Pfizer-BioNTech BNT162b2 vaccine as the primary vaccine series. Normality of the data was determined using Shapiro-Wilk normality test. Non-parametric pairwise analysis for neutralization titers was performed by Wilcoxon matched pairs signed rank test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Journal: Cell Reports Medicine

Article Title: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

doi: 10.1016/j.xcrm.2022.100529

Figure Lengend Snippet: Neutralization antibody responses against WA1/2020, B.1.351, and B.1.1.529 SARS-CoV-2 variants post-mRNA vaccination (A–D) Data from the following cohorts are shown: (A) naive individuals 2–4 weeks after the second dose (n = 24), (B) naive individuals 6 months after the second dose (n = 25), (C) recovered individuals who received the primary mRNA vaccination series (n = 37), and (D) naive vaccinated individuals who received a third dose (n = 52). In (A)–(D), the FRNT 50 GMTs for WA1/2020, B.1.351, and B.1.1.529 are shown with respective fold changes in comparison with the WA1/2020. A pie chart above each graph shows the frequency of individuals who have titers above (Responders) or below (Non-responders) the limit of detection (LOD). The connecting lines between the variants represent matched serum samples. The horizontal dashed lines along the x axis indicate the LOD (FRNT 50 GMT = 10). Blue circles represent individuals who received the Moderna mRNA-1273 vaccine as the primary vaccine series, and the red circles represent individuals who received the Pfizer-BioNTech BNT162b2 vaccine as the primary vaccine series. Normality of the data was determined using Shapiro-Wilk normality test. Non-parametric pairwise analysis for neutralization titers was performed by Wilcoxon matched pairs signed rank test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Article Snippet: nCoV/USA_WA1/2020 (WA/1), closely resembling the original Wuhan strain and resembles the spike used in the mRNA-1273 and Pfizer BioNTech vaccine, was propagated from an infectious SARS-CoV-2 clone as previously described. icSARS-CoV-2 was passaged once to generate a working stock.

Techniques: Neutralization

Demographic and clinical characteristics by inclusion in rapid antigen test analysis

Journal: Journal of the Association of Medical Microbiology and Infectious Disease Canada

Article Title: COVID-19 breakthrough infections in vaccinated participants of the Safety and Efficacy of Preventative COVID Vaccines sub-study

doi: 10.3138/jammi-2022-0011

Figure Lengend Snippet: Demographic and clinical characteristics by inclusion in rapid antigen test analysis

Article Snippet: 47 , M , None , AstraZeneca , mRNA1273 , mRNA1273 , 61 , 183 , 55 , Yes , 1.56.

Techniques:

Characteristics of participants with a positive rapid antigen test

Journal: Journal of the Association of Medical Microbiology and Infectious Disease Canada

Article Title: COVID-19 breakthrough infections in vaccinated participants of the Safety and Efficacy of Preventative COVID Vaccines sub-study

doi: 10.3138/jammi-2022-0011

Figure Lengend Snippet: Characteristics of participants with a positive rapid antigen test

Article Snippet: 47 , M , None , AstraZeneca , mRNA1273 , mRNA1273 , 61 , 183 , 55 , Yes , 1.56.

Techniques: